HAE Stock: Price, Earnings History and SEC Filings
Haemonetics Corporation (HAE) last traded at $119.65, down 0.12% on the latest session and up 13.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $1.14 against an analyst estimate of $1.07, a beat of 6.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
HAE earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $1.14 | $1.07 | +6.54% |
| Mar 2026 | May 7, 2026 | $1.29 | $1.28 | +0.78% |
| Dec 2025 | Feb 5, 2026 | $1.31 | $1.27 | +3.15% |
| Sep 2025 | Nov 6, 2025 | $1.27 | $1.12 | +13.39% |
HAE beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How HAE reacts to earnings
Across its last 8 earnings releases, HAE moved 11.7% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | Before open | +1.70% |
| 2026-05-07 | Before open | +3.23% |
| 2026-02-05 | Before open | -1.41% |
| 2025-11-06 | Before open | +32.31% |
| 2025-08-07 | Before open | -26.58% |
| 2025-05-08 | Before open | +5.85% |
| 2025-02-06 | Before open | -11.58% |
| 2024-11-07 | Before open | +10.71% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
HAE financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2026 | $1.3B | $97M | $260M | 7.3% | $2.05 |
| 2025 | $1.4B | $168M | $142M | 12.3% | $3.31 |
| 2024 | $1.3B | $118M | $144M | 9.0% | $2.29 |
| 2023 | $1.2B | $115M | $82M | 9.9% | $2.24 |
| 2022 | $993M | $43M | $76M | 4.4% | $0.84 |
| 2021 | $870M | $79M | $72M | 9.1% | $1.55 |
| 2020 | $988M | $77M | $109M | 7.7% | $1.48 |
| 2019 | $968M | $55M | $40M | 5.7% | $1.04 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for HAE
- 8-K · Oct 8, 2026Regulation FD disclosure
- 8-K · Aug 18, 2026Regulation FD disclosure
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 28, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- DEF 14A · Jun 9, 2026
- 8-K · Jun 5, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-K · May 20, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- 8-K · May 1, 2026Officer or director change
Insider filing activity
HAE insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
HAE news
- How New HAE Data At BioCryst Pharmaceuticals Stock Has Changed Its Investment StoryOct 30, 2026 · finance.yahoo.com
- GEHC vs. HAE: Which Stock Is the Better Value Option?Oct 29, 2026 · finance.yahoo.com
- Blood Plasma Name Hits Highs On FDA Approval As Earnings LoomOct 28, 2026 · finance.yahoo.com
- Haemonetics Corporation (HAE) Gains on Strong Plasma Growth and Higher Guidance, Ariel Appreciation Fund SaysOct 28, 2026 · finance.yahoo.com
- All You Need to Know About Haemonetics (HAE) Rating Upgrade to BuyOct 27, 2026 · finance.yahoo.com
- Haemonetics (HAE): Buy, Sell, or Hold Post Q2 Earnings?Oct 21, 2026 · finance.yahoo.com
- Nasdaq Jumps Past 1 Percent as VIX Swings While Dow Dips Below Its 50-Day LineOct 19, 2026 · finance.yahoo.com
- Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure SystemOct 19, 2026 · finance.yahoo.com
About Haemonetics Corporation
Haemonetics Corporation (HAE) is a US-listed public company on NYSE. The SEC classifies its business as Surgical & Medical Instruments & Apparatus. It is incorporated in MA. Its fiscal year ends in April.